US 12,329,757 B2
Methods for increasing sepiapterin plasma exposure
Neil Smith, Cary, NC (US); and Jonathan Reis, Brookline, MA (US)
Assigned to PTC Therapeutics MP, Inc., Warren, NJ (US)
Filed by PTC Therapeutics MP, Inc., South Plainfield, NJ (US)
Filed on Mar. 31, 2023, as Appl. No. 18/129,177.
Application 18/129,177 is a continuation of application No. 17/059,719, granted, now 11,617,752, issued on Apr. 4, 2023, previously published as PCT/US2019/034523, filed on May 30, 2019.
Claims priority of provisional application 62/822,376, filed on Mar. 22, 2019.
Claims priority of provisional application 62/771,398, filed on Nov. 26, 2018.
Claims priority of provisional application 62/677,943, filed on May 30, 2018.
Claims priority of application No. 2019/37663 (GC), filed on May 28, 2019.
Prior Publication US 2023/0381181 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating a BH4-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, without food, wherein the BH4-related disorder is phenylketonuria.